Market Trends of Bio-process Technology Industry
Recombinant Protein Segment Expected to Witness Significant Growth Over the Forecast Period.
- The industrial synthesis of recombinant proteins that are important for therapeutic and preventative purposes depends on the development of effective bioprocessing techniques.
- Current developments in the various fields of bioprocessing are being used to provide efficient methods for creating recombinant proteins. These include the use of high-throughput devices for effective bioprocess optimization and of disposable systems, continuous upstream processing, continuous chromatography, integrated continuous bioprocessing, quality by design, and process analytical technologies to achieve a quality product with a higher yield.
- The recombinant protein segment is expected to witness significant growth over the forecast period owing to the growing demand for recombinant proteins for therapeutic applications. Moreover, the recombinant therapeutic proteins provide essential therapies for various diseases, such as diabetes, cancer, infectious diseases, hemophilia, and anemia.
- Furthermore, recombinant proteins are valuable tools in understanding protein-protein interactions, and the increasing research and development and technological advancements are also expected to drive the growth of this segment.
- For instance, in October 2022, Larimar Therapeutics Inc. reported issuing a US patent for the protection of CTI-1601. CTI-1601 is a recombinant fusion protein intended to deliver human frataxin to the mitochondria of patients with Friedreich's ataxia who cannot produce enough of this essential protein.
- Similarly, in February 2021, Sanofi and GSK promulgated the initiation of a new randomized, double-blind, multi-center dose-finding Phase 2 study of their adjuvanted recombinant protein-based COVID-19 vaccine with 720 volunteers. Thus, innovation in healthcare solutions and the development of new recombinant protein-based drugs are driving the segment's growth.
- The increasing prevalence of chronic diseases like diabetes also boosts the demand for recombinant proteins. For instance, IDF reported that 537 million people (20-79 years old) had diabetes in 2021. This number is expected to increase by 643 million diabetics worldwide by 2030 and 783 million by 2045. With the increase in the diabetic population, the demand for recombinant proteins in the therapeutics segment is likely to show lucrative growth in the coming years, thereby contributing to the development of this segment.
- Thus, due to the growing demand for recombinant proteins for therapeutic applications and new product launches, the segment is expected to witness significant growth over the forecast period.
Understand The Key Trends Shaping This Market
Download PDF
North America Expected to Witness Significant Growth Over the Forecast Period.
- North America is expected to witness significant growth over the forecast period owing to government support for promoting bioprocess technologies, rising medical expenditure, and developing healthcare infrastructure. In addition, the region has witnessed major collaborative activities with healthcare giants that are extensively investing in R&D in bioprocess technology development.
- For instance, in March 2022, Stam Biotech raised USD 17 million for its next-generation 3-D printer bioreactor. Similarly, in October 2022, Thermo Fisher Scientific Inc. launched a large-scale cell culture harvesting solution. DynaSpin single-use centrifuge system is a centrifuge that is specifically designed to provide an optimal single-use solution for large-scale cell culture harvesting, to improve and streamline the process by reducing the number of depth filtration cartridges required to complete the harvest process.
- Furthermore, in May 2022, GOOD Meat signed an exclusive multi-year agreement with ABEC Inc. to design, manufacture, install, and commission the largest known bioreactors for avian and mammalian cell culture. Technologies are focused on helping customers in the biopharmaceutical and pharmaceutical industry to improve the human condition and to provide life-changing drugs to market faster and more efficiently. The collaboration between the companies has leveraged their complementary strengths to develop specific workflows, which bridge the gap between analytical and process solutions.
- These major biopharmaceutical companies are expanding and boosting the biopharmaceutical segment in North America. For instance, in October 2021, 3M Health Care and Thermo Fisher Scientific collaborated to meet the growing demand for protein-based therapeutics. Manufacturers need advanced technologies and solutions that support reliable and consistent manufacturing processes. The collaboration between 3M and Thermo Fisher also enabled the manufacturers to capture high titer, high cell-density cultures to improve harvesting and clarification and optimize manufacturing capacity, quality, and efficiency.
- Thus, the technologies, expansions, and investments by these global biopharmaceutical companies are driving the bioprocess technology market in North America.
Get Analysis on Important Geographic Markets
Download PDF
